Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?

Increased plasma concentrations of proprotein convertase subtilisin/ kexin type 9 or PCSK9, which reduces hepatic uptake of low-density lipoprotein by downregulation of the low-density lipoprotein receptor, have been reported in nephrotic patients and might contribute to hyperlipidemia in nephrotic syndrome. The results of the study by Molina-Jijon et al. found that renal PCSK9 expression was upregulated in the collecting duct of nephrotic patients and animals, suggesting that the kidney might be a major source for plasma PCSK9 in nephrotic syndrome. Copyright (C) 2020, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.